主题：Nucleic Acids Translational Research & Therapeutics (siRNA, miRNA, lncRNA, antisense, CRISPR)
第二届广州核酸国际论坛（CNAF）以核酸转化研究与治疗为主题，旨在推动核酸研究和治疗药物的发展，加强中国与国际的交流合作，促进中国核酸生物产业的进步，展望核酸技术作为创新药物第三大发展引擎的美好前景。
本届论坛特邀20多位国际顶级科学家和企业家参会演讲，嘉宾囊括诺贝尔奖得主、世界百强药企的高级主管、世界顶级学府的著名教授、核酸制药上市公司的总裁、核酸治疗世界联盟主席等，内容涵盖RNAi、microRNA、lncRNAantisense、mRNA、exon-skipping、CRISPR等核酸技术最新进展，包括从核酸基础研究到产业化，从临床前开发到临床研究，并分享去年世界首个核酸药物成功上市的经验。论坛的召开，将为国内科学家及研究生提供与本领域学术权威面对面交流的难得机会，为国内从事生物制药的企业单位提供与世界知名药企建立合作的纽带。
我们期待与您相聚美丽羊城，共同迎接核酸治疗时代的来临！
主办单位：
“***”专家联谊会生物医药和生命科学专业委员会
中国生化与分子生物学会核糖核酸专业委员会
中国科学院广州生物医药与健康研究院
呼吸疾病国家重点实验室
中山大学
承办单位：
广州市锐博生物科技有限公司
开幕主旨演讲
Craig Mello教授
美国麻省大学医学院教授
2006年诺贝尔生理学或医学奖获得者
主旨演讲
Troels Koch博士 Ekkehard Leberer教授
丹麦Santaris/Roche制药公司 法国赛诺菲研发联盟管理高级总监
首席技术官，研发副总裁 IMI COMPACT Consortium常务董事
Muthiah Manoharan博士 Brett Monia博士
美国Alnylam制药公司 美国Isis制药公司高级副总裁
高级副总裁,新药开发负责人 Oligonucleotide Therapeutics Society当选主席
大会拟定议程：
| Wed, Nov 5, 2014 | ||
| Registration 13:00-18:00 | ||
| Thu, Nov 06, 2014 (Day 1) | ||
|
| Chair | Mano Manoharan, PhD Senior Vice President, Alnylam Pharmaceuticals, USA |
| 08:30-08:45 | Introduction | CNAF Organizing Committee |
| 08:45-09:30 | Opening Keynote | Craig Mello, PhD Professor, University of Massachusetts Medical School, HHMI, 2006 Nobel Prize Winner, USA Title: RNA-guided genome defense and new frontiers in biotech and medicine |
| 09:30-10:10 | Keynote | Brett Monia, PhD Senior Vice President, Isis Pharmaceuticals, OTS President, USA Title: Transforming drug discovery for human therapeutics with antisense technology |
| 10:10-10:35 | Plenary | Judy Lieberman, MD, PhD Professor, Program Chair, Harvard Medical School, USA Title: Targeted gene knockdown to treat cancer |
| 10:35-10:55 | Tea Break | |
| 10:55-11:20 | Plenary | Matthew Porteus, MD, PhD Professor, Stanford School of Medicine, CRISPR Therapeutics Founder, USA Title: Genome editing using engineered nucleases |
| 11:20-11:45 | Plenary | Erwei Song, MD, PhD Professor and Vice Dean, Sun Yat-Sen Memorial Hospital, China Title: BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10 |
| 11:45-12:00 | Technology | Rick Hogrefe, PhD Founder, President and Chief Executive Officer, TriLink BioTechnologies Title: Designing a mRNA therapeutic suitable for scale up |
| 12:00-13:30 | Lunch | |
| 13:30-13:35 | Chair | Brett Monia, PhD Senior Vice President, Isis Pharmaceuticals, OTS President, USA |
| 13:35-14:15 | Keynote | Troels Koch, PhD Senior Vice President and Chief Technology Officer, Santaris / Roche, Denmark Title: LNA antisense – concepts & status |
| 14:15-14:40 | Plenary | Dmitry Samarsky, PhD Executive Vice President, Technology Development, RiboBio, China Title: In vivo delivery of therapeutic oligonucleotides and potential applications for cancer |
| 14:40-15:05 | Plenary | Georg Sczakiel, PhD Professor, University of Lübeck, Germany Title: Target RNA is involved in guide strand loading of Argonaute-2 and siRNA-induced RNA interference |
| 15:05-15:25 | Tea Break | |
| 15:25-15:50 | Plenary | Peixuan Guo, PhD Professor, William S. Farish Fund Endowed Chair, University of Kentucky, USA Title: A new generation of drugs from the emerging field of RNA nanotechnology |
| 15:50-16:15 | Plenary | Yi Jin, PhD Executive Vice President, Suzhou Ribo Life Science, China Title: RNAi based therapeutics for Hepatitis B |
| 16:15-16:30 | Technology | Suresh Srivastava, PhD Founder and President, ChemGenes, USA Title: BMEG oligonucleotides for efficient cellular delivery for therapeutic and molecular biological applications |
| 16:30-16:55 | Plenary | David Lewis, PhD Chief Scientific Officer, Arrowhead Research Corporation, USA Title: Using Dynamic Polyconjugate® (DPC) technology to advance RNAi-based therapeutics |
| 16:55-17:00 | Day End | CNAF Organizing Committee |
| Fri, Nov 07, 2014 (Day 2) | ||
| 09:00-09:05 | Chair | Troels Koch, PhD Senior Vice President and Chief Technology Officer, Santaris / Roche, Denmark |
| 09:05-09:45 | Keynote | Ekkehard Leberer, PhD Professor, Senior Director of R&D Alliance Management, Sanofi, Germany Title: Nucleic acid therapeutics: opportunities and challenges for innovation in drug development |
| 09:45-10:10 | Plenary | William Marshall, PhD President and Chief Executive Officer, Board Director, miRagen Therapeutics, USA Title: Discovery and development of microRNA targeting therapeutics |
| 10:10-10:35 | Plenary | Micky Tortorella, PhD Chief Technology Officer and Vice President for Drug Discovery and Technology Transfer, Guangzhou Institutes of Biomedicine and Health, China Title: Intra-articular delivery of siRNA-conjugates as new disease modifying osteoarthritis drugs |
| 10:35-10:55 | Tea Break | |
| 10:55-11:20 | Plenary | Chengyu Jiang, PhD Professor, Chair, Peking Union Medical College, CAMS, China Title: Hsa-miR-1246, hsa-miR-320a and hsa-miR-196b-5p inhibitors can reduce the cytotoxicity of Ebola virus glycoprotein in vitro |
| 11:20-11:45 | Plenary | Marc Lemaitre, PhD Chief Executive Officer, Sirnaomics, USA / China Title: Improving siRNA therapeutics using polymer-nanoparticle (PNP) delivery: recent pre-clinical results with STP705 against skin scars |
| 11:45-12:00 | Technology | Kimo Sanderson Vice President, Asahi Kasei, Japan Title: Therapeutic oligonucleotides from discovery to development: the importance of proper production and scale up |
| 12:00-13:30 | Lunch | |
| 13:30-13:35 | Chair | William Marshall, PhD President, Chief Executive Officer, Board Director, miRagen Therapeutics, USA |
| 13:35-14:15 | Keynote | Mano Manoharan, PhD Senior Vice President, Alnylam Pharmaceuticals, USA Title: Chemical strategies for systemic delivery of RNAi drugs |
| 14:15-14:40 | Plenary | Dirk Haussecker, PhD Founder and Curator, RNAi Therapeutics Blog, Germany Title: RNA therapeutics emerging as major drug discovery engine |
| 14:40-15:05 | Plenary | TBD |
| 15:05-15:20 | Technology | Carina Andersson, PhD Marketing Head, GE, USA Title: A manufacturing solution of oligonucleotides |
| 15:20-15:40 | Tea Break | |
| 15:40-16:05 | Plenary | Sven Klussmann, PhD Chief Scientific Officer, NOXXON Pharma, Germany Title: From bench to bedside – the conversion of mirror-image oligonucleotides into therapeutics |
| 16:05-16:30 | Plenary | Ryszard Kole, PhD Distinguished Scientist, Professor, Sarepta Therapeutics, USA Title: Eteplirsen, a phosphorodiamidate morpholino oligonucleotide, as treatment for Duchenne muscular dystrophy (DMD) |
| 16:30-16:55 | Plenary | René Thürmer, PhD Deputy Head of the Unit Pharmaceutical Biotechnology, BfArM - Federal Institute for Drugs and Medical Devices, Germany Title: Regulatory aspects of nucleic acids therapeutics |
| 16:55-17:15 | Closing Remarks | Craig Mello, PhD Professor, University of Massachusetts Medical School, HHMI, 2006 Nobel Prize Winner, USA |
会议时间：2014年11月5-7日
会议地点：广州科学城翡翠皇冠假日酒店
会议语言：英语
论坛网站：www.cnaf.org.cn（点此注册）
赞助企业：
白金赞助
金牌赞助
银牌赞助
铜牌赞助
专项赞助
联系我们：
赞助咨询：
杨先生
电话：（020）32290221-641；18933996781
邮箱：sponsorship@cnaf.org.cn
注册及其他咨询：
官小姐
电话：（020）32290221-656
邮箱：register@cnaf.org.cn ; info@cnaf.org.cn
